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In 2019, 10 years have been passed since the introduction of
dabigatran to the market with the specific indication of
managing thromboembolic risk in atrial fibrillation (AF)
patients.1 Since then, three other nonvitamin K antagonist
oral anticoagulants (NOACs) have been introduced and
NOACs have become increasingly popular for stroke preven-
tion in patients with AF.2 One of the advantages of NOACs
over vitamin K antagonists (VKAs) is the absence of continu-
ous monitoring of the international normalized ratio (INR).3
Indeed, while using VKA obtaining and maintaining an
optimal quality of anticoagulation therapy control is essen-
tial to achieve a significant protection from thromboembolic
events and mortality, without increasing bleeding risk.4
However, adherence and persistence to oral anticoagulation
for some patients is problematic and this requires efforts to
improve appropriate prescriptions, to monitor NOAC adher-
ence and implement strategies to improve adherence where
it is found to be suboptimal.3,5 For anticoagulation clinics,
obtaining good INR control and time in the therapeutic range
is the major objective of the clinical management. With less
need for monitoring with NOACs, those patients who do not
follow the prescribed regimen are likely to experience poorer
adherence, and this may not be captured as adherence and
may not be routinely assessed.6
In a recent narrative review, we reported how the rate of
adherence and persistence in NOACs users ranged widely
across studies, with varying settings and patients typology6
and demonstrated how both adherence and persistence
declined over time.6
In the previous issue of Thrombosis and Haemostasis,
Hwang et al explored the issue of NOACs adherence in a
cohort of real-life AF patients enrolled in a single Korean
tertiary referral cardiology department.7 They evaluated the
adherence to treatment, expressed as percentage of pre-
scribed doses taken (PDT), and also evaluated adherence
with the Morisky Medication Adherence Scale (MMAS)-8
tool. In a cohort of 719 AF patients prescribed one of the four
NOACs (apixaban 47.8%, dabigatran 21.2%, rivaroxaban
18.4%, and edoxaban 12.6%), they found that over a mean
(standard deviation [SD]) treatment period of 7.2 (5.7)
months, the mean (SD) PDT for the once-daily NOACs (rivar-
oxaban and edoxaban) was 95.4 (9.1%) and 93.4% (12.7%) for
the twice-daily NOACs (dabigatran and apixaban). Overall,
92.2% of patients reported high adherence (PDT  80%).
Among the various NOACs, use of dabigatran was associated
with the lowest adherence (PDT¼89.8%), while in general
the twice-daily dosing was associated with an increased risk
of reporting poorer adherence (PDT<80%) in the univariate
analysis (odds ratio [OR]: 2.15; 95% confidence interval [CI]:
1.06–4.34). A sensitivity analysis performed excluding dabi-
gatran users found that twice-daily dosing no longer affected
adherence.7
The MMAS-8 was a good predictor of poor adherence,
showing an AUC of 0.751 (p<0.001), with a MMAS-8 3
exhibiting a 63.8% sensitivity and 78.5% specificity for poor
adherence. In a multivariate logistic regression analysis, the
twice-daily NOAC regimen was independently associated
with a MMAS score of 3 (OR: 1.90; 95% CI: 1.35–2.67).7
The data presented appear reassuring in terms of good
adherence with NOAC in this cohort, with less than 10% of
patients reporting a PDT<80%. However, the study does have
some limitations, namely one Korean center only, relatively
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small cohort managed exclusively in a tertiary center with a
limited follow-up period, which may impact the generaliz-
ability of the results.
A recent studyperformedamong theUKprimaryelectronic
health records system (The Health Information Network),
reports more concerning figures regarding OAC adherence.
In this analysis, good adherencewas defined as the proportion
ofdayscovered (PDC)of>80%.Goodadherenceamongusersof
oral anticoagulant drugs was 55.2% overall, being lowest in
VKA users (51.2%) and significantly higher in NOACs users
(dabigatran 66.5%, rivaroxaban 63.1%, and apixaban 64.7%)8
but still far from optimal. This study also showed that the rate
of good adherence was lower in those patients with a shorter
follow-up available. Previous datawere similar indicating that
over time the adherence rate was progressively lower, irre-
spective of the type of NOACs used.6
The paper by Hwang et al addresses an important issue
regarding OAC management, that of adherence. Indeed, the
ability of MMAS-8 to predict the occurrence of a poor
adherence is useful in terms of clinical management of these
patients and could be utilized alongside other tools to
evaluate AF patients. Indeed, the SAMe-TT2R2 score has
been designed to identify those AF patients that would
more likely perform well if prescribed with VKA,9–11 which
is relevant since VKAs are still widely used OAC globally.
Despite all international guidelines currently recom-
mending the use of NOACs over VKA for the majority of AF
patients,12,13 optimal management of these patients should
evaluate the most appropriate oral anticoagulant as part of
an integrated care approach for AF patients.14–16 During the
baseline evaluation of AF patients, use ofMMAS-8 could help
to identify those patients that more likely will have a poor
adherence to treatment and could be used to plan specific
interventions to improve adherence.
Many factors are implicated in adherence to oral anticoag-
ulant therapy among the patient-related factors are demo-
graphics, medical-related, behavioral factors, and patient
understanding.6 Although many strategies to address non-
adherence have been proposed,6 these need to be individually
tailored to the patient based on the personal underlying cause
(s) of non-adherence. Improving adherence to OAC in AF
patients should be a priority of the clinical management of
AF since data indicate that patients more adherent to NOACs
are more likely to have better outcomes.17 Starting antico-
agulation is not enough, we need to ensure that patients are
adherent lifelong by asking about medication adherence and
where non-adherence is identified, working with the patient
to develop strategies to improve adherence andensuring these
are implemented and maintained (►Fig. 1).
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